Remove 2014 Remove Competition Remove Healthcare Remove Healthcare Provider
article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years. The path to real zero.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Liron Fendell

Cadensee

Until back in 2014, I met the team at Schneider Children's Medical Center of Israel. And I was lucky enough the team at Schneider's and Clalit Healthcare , who is the owner of Schneider Hospital. We are seeing a lot of consumer-based healthcare coming from China. How do you are you dealing with competition in that market?

Retail 52
article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

The agreement outlined that Par would keep its generic equivalent off the market for as many as two years, delaying the generic launch till September 30, 2014. These actions allegedly led to the extension of Novartis’ patents. 2021 was a year of continued innovation and change in the Biopharmaceutical industry.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.

Medical 105
article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.

Medical 98